Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
1. In this retrospective cohort study, the incidence of hydroxychloroquine retinopathy was 2.5% at 10 years, increasing to 8.6% at ...
Tag: disease-modifying anti-rheumatic drugs (DMARD)
Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections ...
Initiation of targeted disease-modifying antirheumatic drugs in patients with rheumatoid arthritis not associated with reduced risk of Alzheimer disease and related dementia
1. There were no differences in the risk of Alzheimer disease and related dementia in patients with rheumatoid arthritis treated ...
Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome
1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. ...
Upadacitinib may be superior to abatecept for refractory rheumatoid arthritis
1. Upadacitinib was superior to abatacept in achieving remission at 12 weeks for patients with rheumatoid arthritis refractory to biologic ...